Malignant Pleural Mesothelioma (MPM) Market

Nov 05, 2020

10 likes | 22 Views

In 2017, the therapeutic market of Malignant Pleural Mesothelioma in the seven major markets (i.e the United States, EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan) was USD 290 million. The total incident cases of Malignant Pleural Mesothelioma in the 7MM was 11,431 in 2017. The incident cases of Malignant Pleural Mesothelioma in the United Kingdom and the United States were found to be 2,495 and 2,627 respectively. Some of the key companies in the Malignant Pleural Mesothelioma (MPM) Market include Trizell, AstraZeneca, Hoffmann-La Roche, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Boehringer Ingelheim Limited, Pfizer, Merck KGaA, Sumitomo Dainippon Pharma, Bayer, ImmunoGen, MorphoSys, TCR2 Therapeutics, Kissei Pharmaceutical, Targovax, Atara Biotherapeutics, Bellicum Pharmaceuticals, Takeda and many others. For more details on Malignant Pleural Mesothelioma Market, visit: https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market

DelveInsight

Download Presentation

Malignant Pleural Mesothelioma (MPM) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D